Skip to main content

Remote Job Finders (RJF)

Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss

The anti-TL1A antibody from Merck’s 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside second-quarter earnings.

Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure

The additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major products like the blood thinner Eliquis.

Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab

Pathos AI could pay more than $2 billion to a Jiangsu Alphamab Biopharmaceuticals subsidiary for a late-stage bispecific antibody-drug conjugate for breast cancer, while the financial details of the AstraZeneca agreement were not disclosed.
Scroll to top